Focal segmental glomerulosclerosis history and symptoms: Difference between revisions
Rim Halaby (talk | contribs) |
Olufunmilola (talk | contribs) No edit summary |
||
| Line 19: | Line 19: | ||
Additionally, a positive family history, heroin abuse, chronic viral infections, and use of associated medications must be ruled out during history-taking. | Additionally, a positive family history, heroin abuse, chronic viral infections, and use of associated medications must be ruled out during history-taking. | ||
In contrast, patients with secondary FSGS is often present with non-nephrotic range proteinuria, serum albumin levels that are usually normal, and most importantly, there is no peripheral edema, even when protein excretion exceeds 3 to 4 g/day.<ref name="pmid19578004">{{cite journal| author=Fernandez-Fresnedo G, Segarra A, González E, Alexandru S, Delgado R, Ramos N et al.| title=Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. | journal=Clin J Am Soc Nephrol | year= 2009 | volume= 4 | issue= 8 | pages= 1317-23 | pmid=19578004 | doi=10.2215/CJN.00570109 | pmc=2723972 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19578004 }} </ref> | |||
==References== | ==References== | ||
Revision as of 18:44, 20 October 2016
|
Focal segmental glomerulosclerosis Microchapters |
|
Differentiating Focal segmental glomerulosclerosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Focal segmental glomerulosclerosis history and symptoms On the Web |
|
American Roentgen Ray Society Images of Focal segmental glomerulosclerosis history and symptoms |
|
FDA on Focal segmental glomerulosclerosis history and symptoms |
|
CDC on Focal segmental glomerulosclerosis history and symptoms |
|
Focal segmental glomerulosclerosis history and symptoms in the news |
|
Blogs on Focal segmental glomerulosclerosis history and symptoms |
|
Directions to Hospitals Treating Focal segmental glomerulosclerosis |
|
Risk calculators and risk factors for Focal segmental glomerulosclerosis history and symptoms |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Clinical Presentation
Generally, primary (idiopathic) focal segmental glomerulosclerosis (FSGS) starts abruptly whereas secondary FSGS has a more insidious onset. The hallmark of FSGS is nephrotic-range proteinuria, appearing in approximately 70% of patients.[1][2]
Common signs and symptoms associated with FSGS are shown below[1][2]:
- Frothy/foamy urine suggestive of proteinuria
- Red discoloration of urine suggestive of hematuria may be present
- Headache and blurry vision, suggestive of high blood pressure
- Signs of fluid overload, such as peripheral edema or periorbital edema
- Dyspnea suggestive of pleural or pericardial effusion
- Abdominal fullness suggestive of ascites
- Fatigue and malaise
- Other signs of renal insufficiency
Additionally, a positive family history, heroin abuse, chronic viral infections, and use of associated medications must be ruled out during history-taking.
In contrast, patients with secondary FSGS is often present with non-nephrotic range proteinuria, serum albumin levels that are usually normal, and most importantly, there is no peripheral edema, even when protein excretion exceeds 3 to 4 g/day.[3]
References
- ↑ 1.0 1.1 Rydel JJ, Korbet SM, Borok RZ, Schwartz MM (1995). "Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment". Am J Kidney Dis. 25 (4): 534–42. PMID 7702047.
- ↑ 2.0 2.1 Chun MJ, Korbet SM, Schwartz MM, Lewis EJ (2004). "Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants". J Am Soc Nephrol. 15 (8): 2169–77. doi:10.1097/01.ASN.0000135051.62500.97. PMID 15284302.
- ↑ Fernandez-Fresnedo G, Segarra A, González E, Alexandru S, Delgado R, Ramos N; et al. (2009). "Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis". Clin J Am Soc Nephrol. 4 (8): 1317–23. doi:10.2215/CJN.00570109. PMC 2723972. PMID 19578004.